Immunovant Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Selling, General & Admin	67.91	76.24	77.24	57.28	48.02	54.23
Research & Development	498.09	456.66	360.92	225.43	170.26	101.81
Total Operating Expenses	566	532.9	438.15	282.71	218.28	156.03
Operating Income	-566	-532.9	-438.15	-282.71	-218.28	-156.03
Interest Income	10.94	25.33	24.73	24.95	7.58	-
Other Non-Operating Income (Expense)	1	2.18	0.47	-1.01	-0.25	-0.78
Total Non-Operating Income (Expense)	11.94	27.51	25.2	23.94	7.33	-0.78
Pretax Income	-538.92	-505.39	-412.95	-258.77	-210.95	-156.81
Provision for Income Taxes	-0.7	0.22	0.89	0.57	0.01	-0.08
Net Income	-538.22	-505.61	-413.84	-259.34	-210.96	-156.73
Net Income to Common	-538.22	-505.61	-413.84	-259.34	-210.96	-156.73
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	191	182	152	138	123	110
Shares Outstanding (Diluted)	191	182	152	138	123	110
Shares Change	21.14%	20.35%	9.76%	12.21%	12.21%	24.98%
EPS (Basic)	-2.82	-2.77	-2.73	-1.88	-1.71	-1.43
EPS (Diluted)	-2.82	-2.77	-2.73	-1.88	-1.71	-1.43
EPS Growth	-	-	-	-	-	-
Free Cash Flow	-414.3	-407.32	-376.63	-214.59	-188.39	-106.37
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-2.17	-2.23	-2.48	-1.55	-1.53	-0.97
EBITDA	-565.61	-532.49	-437.78	-282.48	-218.08	-155.91
EBIT	-566	-532.9	-438.15	-282.71	-218.28	-156.03
Effective Tax Rate	0.13%	-0.04%	-0.22%	-0.22%	-0.00%	0.05%

SEC Filings: 10-K · 10-Q